AMRN Amarin Corp

RNS Number:1079C
Amarin Corporation Plc
14 August 2007







                             AMARIN CORPORATION PLC





LONDON, United Kingdom, August 14, 2007 Amarin Corporation plc ("Amarin" or
"Company") has filed its financial results for the six month period ended June
30, 2007 with the SEC on Form 6-K and these financial results are also available
on Amarin's website (www.amarincorp.com).  Amarin's financial results for the
three month and six month periods ended June 30, 2007 were previously announced
on August 1, 2007.



About Amarin

Amarin is committed to improving the lives of patients suffering from diseases
of the central nervous system.  Our goal is to be a leader in the research,
development and commercialization of novel drugs that address unmet patient
needs.



Amarin's core development pipeline includes, in addition to Miraxion for several
therapeutic indications, four other key development programs in Parkinson's
disease, epilepsy seizures, memory and cognition and our proprietary
pre-clinical combinatorial lipid program.



Amarin has its primary stock market listing in the U.S. on the NASDAQ Capital
Market ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN")
and IEX ("H2E"), respectively.



For press releases and other corporate information, visit the Amarin website at
http://www.amarincorp.com.  Information on our website does not form part of
this press release.



Contacts:

Amarin
+44 (0) 207 907 2442

Rick Stewart
Chief Executive Officer

Alan Cooke
President & Chief Financial Officer

investor.relations@amarincorp.com



Investors:

Lippert/Heilshorn & Associates, Inc.                       +1 212 838 3777

Anne Marie Fields

Bruce Voss                                                                  +1
310 691 7100



Media:

Powerscourt                                                                +44
(0) 207 250 1446

Rory Godson

Sarah Daly





Nomad:

Davy

Fergal Meegan
   +353 (0) 1 679 6363



Disclosure Notice:



The information contained in this document is as of August 14, 2007.  Amarin
assumes no obligation to update any forward-looking statements contained in this
document as a result of new information or future events or developments.  This
document contains forward-looking statements about Amarin's financial condition,
results of operations, business prospects and products in research that involve
substantial risks and uncertainties.  You can identify these statements by the
fact that they use words such as "will", "anticipate", "estimate", "expect",
"project", "forecast", "intend", "plan", "believe" and other words and terms of
similar meaning in connection with any discussion of future operating or
financial performance or events.  Among the factors that could cause actual
results to differ materially from those described or projected herein are the
following: risks relating to the Company's ability to maintain its Nasdaq
listing (including the risk that the Company may not be able to achieve
compliance with the Nasdaq minimum bid price and/or other continued listing
criteria within the required timeframe or at all and the risk that the Company
may not be able to successfully appeal a Nasdaq delisting determination); the
success of Amarin's research and development activities; decisions by regulatory
authorities regarding whether and when to approve Amarin's drug applications, as
well as their decisions regarding labeling and other matters that could affect
the commercial potential of Amarin's products; the speed with which regulatory
authorizations, pricing approvals and product launches may be achieved; the
success with which developed products may be commercialized; competitive
developments affecting Amarin's products under development; the effect of
possible domestic and foreign legislation or regulatory action affecting, among
other things, pharmaceutical pricing and reimbursement, including under Medicaid
and Medicare in the United States, and involuntary approval of prescription
medicines for over-the-counter use; Amarin's ability to protect its patents and
other intellectual property; claims and concerns that may arise regarding the
safety or efficacy of Amarin's product candidates; governmental laws and
regulations affecting Amarin's operations, including those affecting taxation;
Amarin's ability to maintain sufficient cash and other liquid resources to meet
its operating requirements; general changes in International and US generally
accepted accounting principles; growth in costs and expenses; and the impact of
acquisitions, divestitures and other unusual items. A further list and
description of these risks, uncertainties and other matters can be found in
Amarin's Form 20-F for the fiscal year ended December 31, 2006, filed with the
SEC on March 5 2007, Amarin's statutory annual report for the year ended 31
December, 2006 furnished on a Form 6-K to the SEC on May 9, 2007 and in its
Reports of Foreign Issuer on Form 6-K furnished to the SEC.





This announcement has been issued through the Companies Announcement Service of

                           The Irish Stock Exchange.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

ISEBRGDIBSBGGRS

Amarin (LSE:AMRN)
Historical Stock Chart
From Jun 2024 to Jul 2024

Amarin (LSE:AMRN)
Historical Stock Chart
From Jul 2023 to Jul 2024